Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey
- 1 November 2022
- journal article
- review article
- Published by Elsevier BV in Progress in Cardiovascular Diseases
- Vol. 75, 78-82
- https://doi.org/10.1016/j.pcad.2022.08.007
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular DiseaseJournal of Invasive Cardiology, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesHypertension, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in AdultsJournal of Invasive Cardiology, 2018
- Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.JAMA, 2017
- Statin Use for the Primary Prevention of Cardiovascular Disease in AdultsJAMA, 2016
- Practice-Level Variation in Statin Use Among Patients With DiabetesJournal of Invasive Cardiology, 2016
- Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular EventsJAMA Cardiology, 2016
- Clinical Update: Cardiovascular Disease in Diabetes MellitusJournal of the American College of Cardiology, 2016
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular RiskJournal of the American College of Cardiology, 2014
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010